Compare Medpace Holdings Inc (MEDP) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Newmont Corporation — how do they compare? Medpace Holdings Inc trades at $616.26 (market cap $16.82B), while Newmont Corporation trades at $118.27 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 7.2× Medpace Holdings Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Newmont Corporation for 58 Days on average.
| MEDP | NEM | |
|---|---|---|
Market Cap | $16.82B | $121.75B |
Volume | 223,093 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $630.19 | $135.14 |
52-Week Low | $393.42 | $78.63 |
Typical Hold Time | 14 Days | 58 Days |
Enterprise Value | $16.44B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Newmont (NEM) trades at $118.23, up 4.13% today, supported by strong earnings beats and record free cash flow. The stock shows a bearish technical signal near key support at $114, while fundamentals are robust with a P/E of 14.57, net income margin of 33.36%, and revenue growth to $22.67B in 2025. Analyst consensus is strongly bullish with a $136.83 price target.
The outlook for NEM is positive, driven by operational improvements and a constructive gold market. Key risks include gold price volatility and execution of growth projects. With no analyst sell ratings and strong institutional interest, the stock presents a compelling opportunity for investors seeking exposure to a leading gold producer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
